3.2 Massive & Submassive Pulmonary Embolism

Acute pulmonary embolism (PE) is a life-threatening cardiovascular emergency in which an occlusive thrombus lodges in the pulmonary arterial circulation. In the ICU, clinical presentations range from stable dyspnea to catastrophic obstructive shock and pulseless electrical activity (PEA) arrest. Successful management hinges on rapid, accurate risk stratification that balances the immediate benefits of pulmonary arterial reperfusion against the severe risk of major hemorrhage.

---

Risk Stratification & Clinical Classification

The traditional AHA (2011) and ESC (2019) schemes classify acute PE based on hemodynamic stability, right ventricular (RV) strain, and myocardial biomarker elevation. The terms differ in one important way: the AHA defined submassive PE as normotension with RV dysfunction or myocardial necrosis, whereas the ESC labels a patient intermediate-high risk only when both RV dysfunction on imaging and an elevated troponin are present, and intermediate-low risk when one or neither is present in a patient with an elevated PESI class III-V or sPESI $\ge 1$. A normotensive patient with PESI class I-II or sPESI 0 is low risk.

The 2026 AHA/ACC Acute PE Clinical Categories

The 2026 AHA/ACC/multisociety guideline (Creager et al., Circulation 2026) introduced five categories that replace the massive/submassive vocabulary. Expect both systems in questions, so learn to translate between them:

Key recommendations: a multidisciplinary PE response team (PERT) is recommended to speed decisions; systemic thrombolysis plus anticoagulation is reasonable for Category E1 when bleeding risk is acceptable, and is a rescue option in E2; catheter-directed thrombolysis, mechanical thrombectomy, and surgical embolectomy are reasonable for Category E1 and may be considered for D1-D2; for E2 (refractory shock or arrest), VA-ECMO or other mechanical circulatory support at a capable center can bridge to reperfusion; mechanical thrombectomy is not recommended for Categories A to C1, and routine systemic thrombolysis is not recommended in the lower-risk categories; LMWH is recommended over UFH when initial parenteral anticoagulation is needed; and DOACs are the preferred oral agents.

Defining RV Dysfunction

• Echocardiographic Criteria: Right ventricular enlargement with an RV/LV end-diastolic diameter ratio $>0.9$ to $1.0$ in the apical 4-chamber view; McConnell's sign (akinesis of the mid-free RV wall with normal or hyperdynamic apical contraction); decreased tricuspid annular plane systolic excursion (TAPSE $<16\text{ mm}$); tricuspid regurgitant jet peak velocity $>2.8\text{ m/s}$; and systolic flattening of the interventricular septum ("D-shaped" left ventricle).
• Computed Tomography Pulmonary Angiography (CTPA) Criteria: RV/LV transverse diameter ratio $>1.0$ in the axial reconstructed views; bowing of the interventricular septum toward the left ventricle; and retrograde reflux of intravenous contrast medium into the inferior vena cava and hepatic veins.

Defining Myocardial Injury

• Cardiac Troponin I or T: Elevation above the 99th percentile upper reference limit reflects acute ischemic necrosis of RV subendocardial myocytes subjected to high wall tension.
• Brain Natriuretic Peptides (BNP / NT-proBNP): Elevation reflects acute neurohormonal stretch of the overloaded right ventricular myocardium.

---

Systemic Thrombolytic Therapy

Indications

Systemic thrombolysis is the long-standing first-line reperfusion therapy for massive (high-risk; 2026 Category E) pulmonary embolism in patients without absolute contraindications (Class 2a in the 2026 AHA/ACC guideline; Class 1 in ESC 2019). In patients with submassive (intermediate-high-risk) PE, routine upfront systemic thrombolysis is not recommended; it is reserved as rescue therapy for patients who develop objective clinical signs of hemodynamic decompensation (hypotension, worsening lactic acidosis, end-organ hypoperfusion) despite therapeutic anticoagulation.

Dosing Regimens

• Standard Infusion Regimen: Recombinant tissue plasminogen activator (Alteplase / rtPA) 100 mg IV administered as a continuous infusion over 2 hours.
• Cardiac Arrest / Peri-Arrest Regimen: In patients with PE-induced cardiac arrest or imminent hemodynamic collapse, an accelerated bolus of 50 mg IV over 2 minutes is administered. If return of spontaneous circulation (ROSC) is not attained after 15 minutes, a second 50 mg IV bolus may be given.
• Tenecteplase: Weight-based single IV bolus (30 to 50 mg over 5 to 10 seconds), studied extensively in clinical trials.

Evidence & Landmark Trials: The PEITHO Trial

The PEITHO Trial (Pulmonary Embolism Thrombolysis Study, NEJM 2014) was a randomized, double-blind trial that evaluated 1,006 patients with intermediate-risk PE (normotensive with both RV dysfunction on echo/CT and elevated troponin). Patients were assigned to receive tenecteplase plus unfractionated heparin versus placebo plus unfractionated heparin:

• Primary Efficacy Endpoint: Tenecteplase significantly reduced the composite endpoint of all-cause mortality or hemodynamic collapse within 7 days ($2.6\%$ vs. $5.6\%$, $p = 0.02$). This reduction was driven almost entirely by the prevention of hemodynamic collapse.
• Bleeding Harm: Tenecteplase caused a significant, unacceptable increase in major extracranial bleeding ($6.3\%$ vs. $1.2\%$, $p < 0.001$) and a tenfold increase in intracranial hemorrhage / hemorrhagic stroke ($2.0\%$ vs. $0.2\%$, $p = 0.003$).
• 30-Day Mortality: There was no statistically significant difference in 30-day all-cause mortality ($2.4\%$ vs. $3.2\%$, $p = 0.42$).

The MOPETT Trial and "Moderate PE"

The MOPETT trial (Moderate PE Treated with Thrombolysis) evaluated "safe-dose" alteplase (50 mg over 2 hours) in intermediate PE. It demonstrated accelerated reduction in pulmonary artery pressures without fatal bleeding complications, but was underpowered for hard clinical and mortality endpoints.

---

Contraindications to Systemic Thrombolysis

Contraindications to Systemic Thrombolysis in Pulmonary Embolism:

ABSOLUTE CONTRAINDICATIONS (Reperfusion must use mechanical/surgical modalities):
├── Any prior history of intracranial hemorrhage or hemorrhagic stroke
├── Known structural cerebral vascular lesion (e.g., arteriovenous malformation, aneurysm)
├── Known malignant intracranial neoplasm (primary or metastatic)
├── Ischemic stroke within the preceding 3 months
├── Suspected aortic dissection
├── Active internal bleeding or bleeding diathesis (excluding menses)
└── Significant closed-head or facial trauma within the preceding 3 months

RELATIVE CONTRAINDICATIONS (Weigh against immediate mortality risk of massive PE):
├── Severe uncontrolled hypertension on presentation (SBP >180 mmHg or DBP >110 mmHg)
├── History of chronic, poorly controlled hypertension
├── Ischemic stroke older than 3 months
├── Major surgery within the preceding 3 weeks
├── Recent internal bleeding within 2 to 4 weeks (e.g., gastrointestinal hemorrhage)
├── Non-compressible vascular punctures (e.g., subclavian/internal jugular lines)
├── Prolonged or traumatic cardiopulmonary resuscitation (>10 minutes)
├── Active therapeutic oral anticoagulation (e.g., INR ≥1.7 or direct oral anticoagulant)
├── Pregnancy or first postpartum week
└── Active peptic ulcer disease

---

Catheter-Directed Therapies & Percutaneous Thrombectomy

Catheter-directed therapies (CDT) have emerged as essential therapeutic modalities for patients with massive PE who harbor contraindications to systemic thrombolytic therapy, patients who have failed systemic thrombolysis, and select patients with intermediate-high-risk PE possessing high clinical bleeding risk.

                    Pulmonary Artery Catheter Interventions
                                      │
           ┌──────────────────────────┴──────────────────────────┐
           ▼                                                     ▼
Ultrasound-Assisted Catheter Thrombolysis          Large-Bore Mechanical Thrombectomy
(EKOS System)                                     (Inari FlowTriever, Penumbra Lightning)
• Combines high-frequency ultrasound + local rtPA  • Aspiration / mechanical extraction
• Low rtPA dose: 0.5–1.0 mg/hr/catheter           • Zero thrombolytic drug administered
• Total dose: 12–24 mg over 12–24 hours           • Immediate mechanical clot debulking
• Studied in ULTIMA and SEATTLE II               • Studied in FLARE and the FLASH registry

Modalities

1. Ultrasound-Assisted Catheter-Directed Thrombolysis (EKOS): Utilizes multi-sidehole infusion catheters containing ultrasound cores. High-frequency (2.2 MHz), low-power acoustic ultrasound energy loosens and uncrosslinks fibrin strands, increasing clot permeability to low-dose local alteplase infusions (typically 0.5 to 1.0 mg/hour per catheter; total dose 12 to 24 mg). The ULTIMA trial demonstrated superior reversal of RV enlargement at 24 hours compared to heparin alone without major bleeding.
2. Large-Bore Mechanical Aspiration Thrombectomy: Systems such as the Inari FlowTriever (16–24 French) and Penumbra Lightning aspirate and extract large, organized thrombi directly from pulmonary arterial trunks without requiring any thrombolytic medication. The single-arm FLARE study and the FLASH registry showed immediate reductions in mean pulmonary artery pressure and RV/LV ratio with low major bleeding rates ($<1.5\%$). These are surrogate outcomes; randomized trials with clinical endpoints (such as HI-PEITHO and PEERLESS) are reshaping the evidence base, and mechanical thrombectomy is not recommended for Categories A to C1.

---

Surgical Pulmonary Embolectomy

Surgical embolectomy under cardiopulmonary bypass with median sternotomy is indicated for:

• Massive PE with absolute contraindications to systemic thrombolysis
• Massive PE with refractory shock despite systemic thrombolysis or catheter intervention
• Right ventricular thrombus-in-transit straddling a patent foramen ovale (high risk of paradoxical systemic arterial embolization and stroke)

In modern centers with dedicated multidisciplinary Pulmonary Embolism Response Teams (PERT), perioperative survival for surgical embolectomy exceeds 85% to 90% when performed prior to the onset of irreversible multi-organ failure or cardiac arrest.

---

Parenteral Anticoagulation: UFH vs. LMWH

Immediate parenteral anticoagulation must be instituted upon high clinical suspicion of acute PE, even while confirmatory imaging is being arranged, provided there is no active hemorrhage.

Unfractionated Heparin (UFH)

• Dosing: Intravenous bolus of 80 units/kg, followed by a continuous maintenance infusion of 18 units/kg/hour, titrated to an anti-factor Xa level of $0.3–0.7\text{ IU/mL}$ (or aPTT 1.5 to 2.5 times control).
• When UFH Is Still Chosen (sickest Category E patients, imminent procedures, severe renal failure):
  • Short biological half-life (60 to 90 minutes after stopping infusion).
  • Complete and rapid reversibility with protamine sulfate (1 mg protamine neutralizes ~100 units of UFH administered in the preceding 2 hours; maximum dose 50 mg).
  • Safe in severe renal insufficiency ($\text{CrCl} < 30\text{ mL/min}$), as UFH is cleared by the reticuloendothelial system and endothelial cells rather than renal excretion.
  • Seamless interruption prior to urgent catheter intervention or surgical embolectomy.

Low-Molecular-Weight Heparin (LMWH)

• Dosing: Enoxaparin 1 mg/kg subcutaneously every 12 hours (or 1.5 mg/kg once daily); dalteparin 200 units/kg once daily.
• Role: Recommended over UFH (2026 AHA/ACC) for hospitalized patients who need initial parenteral anticoagulation, because a meta-analysis showed less recurrent VTE without more bleeding, plus more predictable bioavailability, lower incidence of heparin-induced thrombocytopenia (HIT), and no requirement for laboratory monitoring. However, LMWH is contraindicated or requires dose reduction/anti-Xa monitoring in severe renal failure ($\text{CrCl} < 30\text{ mL/min}$) and cannot be fully neutralized by protamine (only ~60% reversed).

---

Mechanical Circulatory Support: Venoarterial (VA) ECMO

In catastrophic massive pulmonary embolism complicated by refractory obstructive shock or cardiac arrest (PEA), venoarterial extracorporeal membrane oxygenation (VA-ECMO) can be life-saving.

By draining deoxygenated venous blood from the femoral vein/right atrium and pumping oxygenated blood into the femoral artery, VA-ECMO accomplishes two critical goals:

1. Completely decompresses the acutely failing, overloaded right ventricle.
2. Restores systemic end-organ perfusion and arterial oxygenation.

VA-ECMO serves as an emergent hemodynamic bridge to definitive catheter thrombectomy, surgical embolectomy, or delayed clot dissolution under systemic thrombolysis or anticoagulation.

---

Inferior Vena Cava (IVC) Filters

Indications

1. Absolute contraindication to anticoagulation in the setting of acute proximal DVT or acute PE (e.g., active major intracranial or gastrointestinal bleeding, major trauma, planned urgent surgery).
2. Recurrent, objectively documented PE despite proven therapeutic anticoagulation.
3. Massive PE with severe residual cardiopulmonary compromise where a subsequent small embolus would be fatal (controversial; temporary protection).

Complications & Long-Term Outcomes (PREPIC Trial)

The landmark PREPIC trial demonstrated that permanent IVC filters significantly reduced the initial risk of recurrent PE, but significantly increased the long-term incidence of deep vein thrombosis ($20.8\%$ vs. $11.6\%$, $p = 0.02$) with no overall difference in survival.

Retrievable IVC filters should be removed as soon as the bleeding risk subsides and therapeutic anticoagulation can be safely initiated. Complications of indwelling filters include filter thrombosis, IVC occlusion, migration, strut fracture, tilt, and secondary perforation into the duodenum, aorta, or retroperitoneum.